0B68 Hann, Hie-Won L - Thomas Jefferson University - Thomas Jefferson University

Hie-Won L. Hann, MD

Contact Dr. Hann

32 South 10th Street
Main Building, Suite 480
Philadelphia, PA 19107

(215) 955-8900
(215) 503-2527 fax

Most Recent Peer-reviewed Publications

  1. Then and now: The progress in hepatitis B treatment over the past 20 years
  2. Randomized comparison of Tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B
  3. HBV-related health behaviors in a socio-cultural context: Perspectives from Khmers and Koreans
  4. Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma
  5. Correlates of Hepatitis B Virus Health-Related Behaviors of Korean Americans: A Situation-Specific Nursing Theory
  6. Comprehensive Analysis of Common Serum Liver Enzymes as Prospective Predictors of Hepatocellular Carcinoma in HBV Patients
  7. Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection - Results from a clinic-based longitudinal cohort
  8. Telomere length in circulating serum DNA as a novel non-invasive biomarker for cirrhosis: A nested case-control analysis
  9. Erratum: Recognition and management of HBV infection in a social context (Journal of Cancer Education DOI: 10.1007/s13187-011-0203-5)
  10. Relative telomere length: A novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection
  11. The management of chronic hepatitis B in Asian Americans
  12. Recognition and management of HBV infection in a social context
  13. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance
  14. Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated
  15. Analysis of GP73 in patients with HCC as a function of anti-cancer treatment
  16. Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009)
  17. Telbivudine: An effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses
  18. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir
  19. Response
  20. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B